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Copy number variation analysis increases
the diagnostic yield in muscle diseases
ABSTRACT
Objective: Copy number variants (CNVs) were analyzed from next-generation sequencing data,
with the aim of improving diagnostic yield in skeletal muscle disorder cases.
Methods: Four publicly available bioinformatic analytic tools were used to analyze CNVs from
sequencing data from patients with muscle diseases. The patients were previously analyzed with
a targeted gene panel for single nucleotide variants and small insertions and deletions, without
achieving final diagnosis. Variants detected by multiple CNV analysis tools were verified with
either array comparative genomic hybridization or PCR. The clinical significance of the verified
CNVs was interpreted, considering previously identified variants, segregation studies, and clini-
cal information of the patient cases.
Results: Combining analysis of all different mutation types enabled integration of results and iden-
tified the final cause of the disease in 9 myopathy cases. Complex effects like compound hetero-
zygosity of different mutation types and compound disease arising from variants of different
genes were unraveled. We identified the first large intragenic deletion of the titin (TTN) gene
implicated in the pathogenesis of a severe form of myopathy. Our work also revealed a “double-
trouble” effect in a patient carrying a single heterozygous insertion/deletion mutation in the TTN
gene and a Becker muscular dystrophy causing deletion in the dystrophin gene.
Conclusions: Causative CNVs were identified proving that analysis of CNVs is essential for
increasing the diagnostic yield in muscle diseases. Complex severe muscular dystrophy pheno-
types can be the result of different mutation types but also of the compound effect of 2 different
genetic diseases. Neurol Genet 2017;3:e204; doi: 10.1212/NXG.0000000000000204
GLOSSARY
aCGH 5 array comparative genomic hybridization; BMD 5 Becker muscular dystrophy; CK 5 creatine kinase; CNV 5 copy
number variant; indels5 insertions and deletions; LGMD5 limb-girdle muscular dystrophy;NGS5 next-generation sequenc-
ing; SNV 5 single nucleotide variant.
Next-generation sequencing (NGS) methods have become the most common method for the
genetic diagnosis of genetically heterogeneous disorders.1,2 We have previously developed a tar-
geted NGS gene panel, MyoCap.1 An updated version used here includes probes for the exons of
nearly 300 myopathy genes and candidate genes. Similar platforms are currently in use in many
laboratories.2 The reported diagnostic success rates are significantly higher than those obtained
by traditional gene-by-gene sequencing.2 However, over 50% patients remain undiagnosed
when only concentrating on single nucleotide variants (SNVs) and small insertions and deletions
(indels).2
Copy number variants (CNVs) are defined as genomic deletions or duplications greater than
1 kb in size.3 CNVs cause microdeletion and microduplication syndromes, and they have also
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been associated with several complex dis-
eases.3,4 Generally, studies aiming for the iden-
tification of causative disease variants in
skeletal muscle disorders have not systemati-
cally used CNV screening. Multiplex ligation-
dependent probe amplification has a lower
throughput when the amount of investigated
genes increases.5 Array comparative genomic
hybridization (aCGH) has long been consid-
ered the only reliable and robust platform for
CNV discovery.4 However, in NGS studies,
the diagnostic evaluation may end with a dis-
covery of a single pathogenic or likely patho-
genic mutation before the utilization of
complementary methods, which may lead to
an underestimation of CNV contribution to
diseases. Recently, several CNV analysis tools
for NGS data have been developed and are in
use for routine diagnosis.3,4 Here, we describe
the detection of CNVs from NGS data with
a combination of already available bioinfor-
matic tools.
METHODS Standard protocol approvals, registrations,
and patient consents. DNA samples of muscle disease patients
and healthy family members were obtained from clinicians in dif-
ferent countries. The study was approved by the Coordinating
Ethics Committee of the Hospital District of Helsinki and Uusi-
maa. The samples were obtained according to the Helsinki decla-
ration. Written informed consent was obtained from all patients.
CNV assessment from NGS data. CNVs were analyzed in
smaller batches from NGS data alignment files (.bam) obtained
by analyzing DNA from 791 myopathy patients with MyoCap.1
We used 4 CNV analysis programs: Copy Number Inference
From Exome Reads (CoNIFER) v0.2.2,6 eXome-Hidden Mar-
kov Model (XHMM) v1.1,7 ExomeDepth v1.1.10,8 and COpy
number Detection by EXome sequencing (CODEX) v1.4.0,9
with the recommended default settings of each program.
A minimum of 1-bp overlap was used to determine whether calls
intersecting between different programs originated from the same
CNV. In this article, we prioritize the specific cases with a very
high clinical interest, focusing on 7 variants detected by multiple
programs and verified by using independent tools.
CNV validation. PCR was performed to confirm CNVs in pa-
tients I, IIIa, IIIb, IV, V, VI, and VII. Primers were designed
using Primer3 v4.0.0 (primer3.ut.ee) (table e-1, http://links.
lww.com/NXG/A12), and PCR was performed with DreamTaq
DNA Polymerase (Thermo Fisher Scientific, Waltham, MA)
(figure e-1). A custom aCGH (manuscript in preparation),
investigating 187 of the genes included in MyoCap, was used to
confirm CNV detected in patient IIa. Segregation study in the
family of patient IIa was performed by PCR (table e-1).
RESULTS Table 1 shows the clinical features of pa-
tients in this study, genetic findings, amount of pro-
grams that detected the CNV, and the CNV
verification method.
Patient I was identified to have a heterozygous
FINmaj mutation, an 11-bp insertion/deletion in
the titin (TTN) gene.10 This variant causes dominant
tibial muscular dystrophy, characterized by a late age
at onset, normal or slightly elevated creatine kinase
(CK) levels, and a mild distal phenotype. However,
this patient has proximal weakness and a very high
Table 1 Patient and variant features
ID Sex Onset First symptom Muscle weakness CK
Previous genetic
tests Genetic findings
Detected by n
programs/verified with
I M Early adult Weakness Proximal LL 9x CAPN3a; FKRPa;
LMNAaT; RIM32a
TTN: c.107780_107790
delinsTGAAAGAAAAA1; DMD:
c.(643811_6439-1) _
(c.821711_c.8218-1)del
3/PCR
IIa; IIb M Infancy Weakness, exercise
intolerance
Proximal and distal LL 11x CAPN3a; DYSFa TTN: c.107889delA:p.
(Lys35963Asnfs*) 1 c.
(785511_7856-1)_
(970311_9704-1)del
4/aCGH
IIIa; IIIb F Infancy Weakness, walking
difficulties
Proximal LL, Gowers1 .10x CAPN3a; ANO5a; WES SGCD: c.(?_-1) _(50511_506-1)
del hom
4/PCR
IV M Infancy Walking difficulties Proximal . distal;
Gowers1
20x DMDb CAPN3: c.(309 1 1_310-1) _
(*1_?) hom
2/PCR
V M Early adult Walking difficulties Proximal LL 5–6x None DMD: c.(643811_6439-1) _
(c.821711_c.8218-1)del
3/PCR
VI M Early adult Walking difficulties Muscle atrophy; calf
hypertrophy
10x None DMD: c.(643811_6439-1)_
(c.709811_c.7099-1)del
2/PCR
VII M Infancy Walking difficulties Proximal LL, Gowers1 .10x None DMD: c.(592211_5923-1) _
(629011_6291-1)del
2/PCR
Abbreviations: aCGH 5 array comparative genomic hybridization; CK 5 creatine kinase; hom 5 homozygous; LL 5 lower limbs; NA 5 not available.
Genetic findings are described using the reference transcripts: NM_001267550.1 for TTN, NM_004006.1 for DMD, NM_000231.2 for SGCD, and
NM_000070.2 for CAPN3.
a Sanger sequencing.
bMultiplex ligation-dependent probe amplification.
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CK level. We excluded the presence of other delete-
rious variants in TTN. Surprisingly, the patient was
found to have a previously reported dystrophin
(DMD) deletion (exons 45–55) known to cause
Becker muscular dystrophy (BMD).11
Patient IIa has a previously reported Iberian
frameshift mutation, p.(Lys35963Asnfs*), in the last
exon of TTN usually determining 1 component of
the recessive distal titinopathy phenotype.10 Com-
pared with the other carriers of this variant, this
patient has a more severe disease progression with
proximal weakness, loss of ambulation before the
age of 40 years, and marked hyperCKemia. The
patient had no further causative SNVs or indels in
the TTN gene. We identified a large deletion in TTN
(exons 34–41; figure 1A) in trans with the Iberian
frameshift variant in the proband IIa as well as in
patient IIb, a similarly affected brother. Their healthy
relatives are heterozygous for only one of the afore-
mentioned TTN mutations demonstrating the reces-
sive effect of the detected deletion. The severe distal
and proximal titinopathies were thus caused by the
compound heterozygosity of the Iberian frameshift
and the deletion (figure 2).
Figure 1 Visualizations of copy number variants of patients IIa and IIIa
CoNIFER visualizations of a heterozygous deletion in the TTN in patient IIa (A) and a homozygous deletion in the SGCD in patient IIIa (B) accompanied with
corresponding regions visualized with Integrative Genomics Viewer (IGV). In CoNIFER visualizations, the red line corresponds to the read depths for sample
with deletion and black lines correspond to control samples. In the IGV visualization, the first row shows the sample with deletion and the second row shows
a control sample without deletion.
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Patients IIIa and IIIb, with a severe limb-girdle
muscular dystrophy (LGMD) phenotype, are the
daughters of first-cousin parents. Sanger sequencing
of candidate genes (CAPN3 and ANO5), MyoCap,
and whole-exome sequencing had been performed
without identifying the causative variant. All the
CNV detection programs identified a homozygous
deletion in the SGCD gene (exons 1–5) (figure 1B).
Patient IV is the child of consanguineous parents,
and he has been suffering from lower limb muscular
weakness in the lower limbs since the age of 7. Dele-
tions and duplications in the DMD gene had been
excluded. Immunochemistry showed normal staining
for dystrophin as well as for the sarcoglycans. A homo-
zygous deletion in CAPN3 (exons 2–8) was detected.
In 2 males with an LGMD-like phenotype (pa-
tients V and VI), we found previously reported
DMD deletions explaining the observed proximal mus-
cular weakness. Both patients have in-frame deletions
(exons 45–55 and exons 45–48) causing BMD.11
Patient VII with a Duchenne phenotype was also
included in our screening. As expected, a previously
reported out-of-frame DMD deletion (exons 42–43)
was identified.11
DISCUSSION Genomes are usually analyzed for
SNVs and indels, but studies of CNVs are often
underrepresented. CNVs in muscle diseases have
previously been studied with complementary meth-
ods like targeted aCGH, which still remains the gold
standard technique for CNV detection.4,5 Here, we
show that combining analysis of all different muta-
tion types enables integration of results and identi-
fies the final cause of the disease in several cases.
Complex effects like compound heterozygosity in
patients IIa and IIb and compound genetic disease
arising from variants of different genes in patient I
can be unraveled. It has been suggested that the
number of patients with a combination of 2 or more
genetic diseases is probably underestimated.12 The
phenotypic complexity in these patients may erro-
neously be interpreted as a new genetic disease with
unidentified genetic defect or as a phenotypic expan-
sion for a single disease.12 The proximal phenotype
seen in patient I is mainly due to BMD, as the
typical anterior lower-leg muscle lesions of the
FINmaj TTN mutation may develop only after age
60. However, the identification of multilocus
genomic variants is crucial for a proper genetic
counseling in the family.
The combination of 4 analysis tools aided us to
identify already known and previously unknown
CNVs. CNVs can explain some of the missing her-
itability and undiagnosed cases in skeletal muscle
disorders. An NGS-based strategy for CNV detec-
tion will be of great value for increasing the diagnos-
tic yield in patients affected by mendelian muscle
diseases. Current technology does not adequately
capture repeat expansion diseases such as myotonic
dystrophy or diseases related to other repetitive ele-
ments. Long-read sequencing technologies may fur-
ther help the identification and mapping of CNVs as
well as of repeat expansions. However, the clinical
interpretation of CNVs remains challenging, in par-
ticular for CNVs identified in genes without previ-
ously reported disease causing deletions or
duplications. The inclusion of CNV data in public
databases, e.g., ExAC, could help in pathogenicity
assessment of CNVs.
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